Generic Drug Development CDMO

Introduction When a Complete Response Letter (CRL) is issued for a Generic ANDA under 21 CFR 314.110, the applicant immediately […]

Introduction The choice between the 505(b)(2) vs ANDA Regulatory Pathway depends largely on whether the proposed drug product is an

Introduction Pharmaceutical sponsors can execute a Switch CDMO After ANDA Submission, but the regulatory approach depends on whether the ANDA

Introduction An Abbreviated New Drug Application (ANDA) submission requires stability data from a minimum of three primary exhibit batches, which

Introduction: CDMO support for ANDS can provide generic drug sponsors with the scientific, analytical, manufacturing, and documentation capabilities needed to

Introduction: For any company preparing to file an Abbreviated New Drug Application (ANDA), a Comparative Dissolution Study for ANDA is

Introduction Scaling a GLP-1 analog from preclinical synthesis to Good Manufacturing Practice (GMP) kilogram-scale manufacturing involves moving beyond small-scale discovery

Introduction Supporting a poorly soluble generic API requires an integrated Chemistry, Manufacturing, and Controls (CMC) framework that combines systematic reference-listed

Introduction Executing a successful Generic Metered Dose Inhaler (MDI) ANDA Development program requires a comprehensive weight-of-evidence regulatory framework that demonstrates

Introduction Impurity profiling and structural elucidation for generic small-molecule injectable Abbreviated New Drug Applications (ANDAs) is an essential analytical activity